Busey Trust CO lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,796 shares of the biopharmaceutical company’s stock after purchasing an additional 1,040 shares during the period. Busey Trust CO’s holdings in Gilead Sciences were worth $6,779,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of Gilead Sciences by 11.6% during the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after purchasing an additional 3,221,439 shares in the last quarter. Northern Trust Corp increased its position in shares of Gilead Sciences by 2.0% during the second quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock worth $1,191,754,000 after purchasing an additional 325,246 shares in the last quarter. Sanders Capital LLC increased its position in shares of Gilead Sciences by 7.0% during the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after purchasing an additional 696,200 shares in the last quarter. Boston Partners increased its position in shares of Gilead Sciences by 3.1% during the second quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after purchasing an additional 245,805 shares in the last quarter. Finally, OppenheimerFunds Inc. increased its position in shares of Gilead Sciences by 0.3% during the second quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock worth $498,599,000 after purchasing an additional 22,916 shares in the last quarter. Institutional investors and hedge funds own 77.99% of the company’s stock.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $227,505,229.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 150,000 shares of company stock worth $11,502,500 in the last ninety days. 1.16% of the stock is owned by corporate insiders.

A number of analysts have recently commented on the company. Wells Fargo & Co lifted their target price on Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research report on Thursday, July 26th. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, September 29th. Finally, Cantor Fitzgerald began coverage on Gilead Sciences in a report on Monday, October 1st. They set an “overweight” rating and a $87.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $88.24.

NASDAQ GILD opened at $73.59 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. Gilead Sciences, Inc. has a 52-week low of $64.27 and a 52-week high of $89.54. The stock has a market cap of $100.09 billion, a P/E ratio of 8.60, a P/E/G ratio of -3.92 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The firm had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the company posted $2.56 earnings per share. The business’s revenue was down 20.9% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 6.56 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Shareholders of record on Friday, September 14th were issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Thursday, September 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: What Are Treasury Bonds?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.